Effectiveness, Safety and Patient‐Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real‐World Evidence From a Prospective Observational Study
Journal of Viral Hepatitis · 2026
DOI: 10.1111/jvh.70181 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Viral Hepatitis, 2026. Verfasst von Daniele Mengato und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Pharmacy Department, Azienda Ospedale-Università Padova, Padua, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis D, Chronic, Patient Reported Outcome Measures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Chronic hepatitis delta (CHD) is the most severe form of viral hepatitis and is associated with accelerated progression to cirrhosis and liver failure. Bulevirtide has shown promising results in trials, but real‐world data on its effectiveness, safety and impact on patient‐reported outcomes (PROs) remain limited. To evaluate the effectiveness, safety, and PROs (quality‐of life—QoL; adherence) of bulevirtide therapy in CHD patients undergoing a dedicated pharmacist‐led patient‐education program (PEP). A prospective observational study enrolled 31 consecutive CHD patients receiving bulevirtide 2 mg daily at a tertiary referral centre. Virological, biochemical and combined responses were assessed at weeks 24, 48 and 60. QoL (through EQ‐5D‐5L questionnaire), adherence (proportion of days covered), and adverse events were monitored during follow‐up. Bulevirtide significantly reduced HDV‐RNA by week 24 ( p < 0.01), with further reductions at week 48 ( p = 0.05) and 60 ( p < 0.01). Liver tests improved significantly from baseline to week 24 ( p < 0.01) and remained stable. Combined response was achieved in 43.7% of patients by week 60. QoL improved significantly ( p = 0.03), and adherence was excellent (≥ 90%). Adverse events were mostly mild and transient. In real‐world clinical practice, bulevirtide achieved sustained virological and biochemical improvements with favourable safety and quality‐of‐life outcomes, confirming its effectiveness in routine management of CHD. While the 60‐week data ( n = 16) are exploratory due to the sample size, these findings confirm its effectiveness and safety in routine management of CHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Pharmacy Department, Azienda Ospedale-Università Padova, Padua, Italy.
- Gastroenterology and Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Azienda Ospedale-Università Padova, University of Padua, Padua, Italy.
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
- Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine, University of Padua, Padua, Italy.
- General Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, Azienda Ospedale-Università Padova, Padua, Italy.
- Infectious and Tropical Diseases Unit, Azienda Ospedale-Università Padova, Padua, Italy.
ORCID-Profile: Daniele Mengato, Francesco Paolo Russo
Zitieren
APA
Mengato, D., Battistella, S., Cadore, A., Giunco, E. M., Zanaga, P., Zappitelli, T., Romano, A., Tonon, M., Pasin, F., Barbaro, F., Sasset, L., Scribano, L., Gambato, M., Berti, G., Simioni, P., Cattelan, A., Burra, P., Venturini, F., & Russo, F. P. (2026). Effectiveness, Safety and Patient‐Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real‐World Evidence From a Prospective Observational Study. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70181
Vancouver
Mengato D, Battistella S, Cadore A, Giunco EM, Zanaga P, Zappitelli T, et al. Effectiveness, Safety and Patient‐Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real‐World Evidence From a Prospective Observational Study. Journal of Viral Hepatitis. 2026. doi:10.1111/jvh.70181
BibTeX
@article{Mengato2026,
author = {Mengato, Daniele and Battistella, Sara and Cadore, Alessandro and Giunco, Elisabetta Mariavittoria and Zanaga, Paola and Zappitelli, Teresa and Romano, Antonietta and Tonon, Marta and Pasin, Francesca and Barbaro, Francesco and Sasset, Lolita and Scribano, Laura and Gambato, Martina and Berti, Giacomo and Simioni, Paolo and Cattelan, Annamaria and Burra, Patrizia and Venturini, Francesca and Russo, Francesco Paolo},
title = {Effectiveness, Safety and Patient‐Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real‐World Evidence From a Prospective Observational Study},
journal = {Journal of Viral Hepatitis},
year = {2026},
doi = {10.1111/jvh.70181}
}
EUVIMED